Sinocelltech Group Limited: all 81 studies

Page 1 of 1. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10Not yet recruitingNCT07847697Phase 1
• SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruitingNCT07819188Phase 1/2
• SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid TumorsNot yet recruitingNCT07665970Phase 1/2
• SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerRecruitingNCT07662395Phase 2/3
• A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）Not yet recruitingNCT07609251Phase 2
• Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid TumoursNot yet recruitingNCT07594028Phase 1/2
• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07570823Phase 3
• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT07562022Phase 3
• A Clinica Study of SCTC21C in Participants With Systemic Lupus ErythematosusNot yet recruitingNCT07538154Phase 1/2
• Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.RecruitingNCT07437404Phase 3
• A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)RecruitingNCT07388602Phase 3
• A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.RecruitingNCT07362459Phase 3
• A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07297329Phase 3
• Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07244510Phase 2
• Phase I/II Study of SCTB39G in Advanced Solid TumoursNot yet recruitingNCT07077252Phase 1/2
• Phase I/II Study of SCTB39-1 in Advanced Solid TumoursRecruitingNCT07050641Phase 1/2
• A Study of SCTB35 in Patients with Systemic Lupus ErythematosusRecruitingNCT06841042Phase 1/2
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster VaccineNot yet recruitingNCT06801509Phase 1/2
• A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Phase 1/2
• A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.Not yet recruitingNCT06769984Phase 1/2
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus VaccineRecruitingNCT06754605Phase 1/2
• Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMDRecruitingNCT06672536Phase 1/2
• Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.RecruitingNCT06600022Phase 1/2
• A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT06318884Phase 1
• Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Not yet recruitingNCT06304818Phase 1/2
• A Clinical Study of SCTC21C in Participants With CD38+ Hematologic MalignanciesRecruitingNCT06252298Phase 1
• Efficacy and Safety of SCT650C in Participants With Axial SpondyloarthritisNot yet recruitingNCT06197009Phase 2
• A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster VaccinesNot yet recruitingNCT05933512Phase 2
• Evaluate the Safety and Tolerability of SCT650C in Healthy VolunteersNot yet recruitingNCT05894707Phase 1
• This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMDRecruitingNCT05480293Phase 3
• To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Not yet recruitingNCT04709328Phase 2/3
• Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.RecruitingNCT03947567Phase 4
• The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19TerminatedNCT04644185Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 YearsActive, not recruitingNCT06041061Phase 3
• Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023Status unknownNCT05758675
• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownNCT05683561Phase 3
• A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCompletedNCT05652543Phase 2
• SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT05552807Phase 1
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 YearsStatus unknownNCT05522829Phase 2
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 YearsStatus unknownNCT05345873Phase 2
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 YearsStatus unknownNCT05329051Phase 2
• A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster VaccinesStatus unknownNCT05323461Phase 3
• A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 YearsWithdrawnNCT05308602Phase 2
• A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 YearsActive, not recruitingNCT05308576Phase 3
• A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineWithdrawnNCT05239975Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 VaccineStatus unknownNCT05239806Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 VaccineStatus unknownNCT05238454Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 VaccineStatus unknownNCT05238441Phase 2
• A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19WithdrawnNCT05156645Phase 1/2
• The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated AdultsCompletedNCT05148091Phase 1/2
• A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownNCT05060484Phase 2
• The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.Status unknownNCT05043311Phase 1/2
• The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Status unknownNCT05043285Phase 1/2
• A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 YearsStatus unknownNCT04921111Phase 1
• The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive CareStatus unknownNCT04683328Phase 2/3
• The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)Status unknownNCT04564937Phase 1/2
• SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT04560894Phase 2/3
• Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese SubjectsCompletedNCT04483375Phase 1
• Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRCStatus unknownNCT04229537Phase 1
• SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung CancerTerminatedNCT04171284Phase 3
• SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT04146402Phase 3
• Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell CarcinomaStatus unknownNCT04146181Phase 2
• Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.Status unknownNCT03947320Phase 3
• The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque PsoriasisStatus unknownNCT03927352Phase 3
• Pharmacokinetics and Safety in Healthy VolunteersCompletedNCT03917628Phase 1
• SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell CarcinomaStatus unknownNCT03874741Phase 2
• Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or LymphomaStatus unknownNCT03821363Phase 1
• Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Phase 1/2
• Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia ACompletedNCT03815318Phase 3
• Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT03808701Phase 1
• To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung CancerStatus unknownNCT03792074Phase 3
• Safety and Efficacy of SCT200 in Head and Neck Squamous Cell CarcinomaStatus unknownNCT03713372Phase 2
• Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast CancerStatus unknownNCT03692689Phase 2
• Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid TumorsStatus unknownNCT03692520Phase 1
• Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRCStatus unknownNCT03405272Phase 2
• Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia AStatus unknownNCT02921945Phase 3
• Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia AStatus unknownNCT02888223Phase 1
• A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL PatientsStatus unknownNCT02772822Phase 3
• A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaStatus unknownNCT02456207Phase 2
• Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal CancerStatus unknownNCT02211443Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.CompletedNCT02206308Phase 1

← Sinocelltech Group Limited overview and focus areas